RecruitingPhase 2NCT04467671
Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
Studying Mitral atresia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nationwide Children's Hospital
- Principal Investigator
- Christopher Breuer, MD, M.DNationwide Children's Hospital
- Intervention
- Tissue Engineered Vascular Grafts(combination_product)
- Enrollment
- 24 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2027
Study locations (1)
- Nationwide Children's Hospital, Columbus, Ohio, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · Gunze Limited · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04467671 on ClinicalTrials.gov